Rush, AJ, Aaronson, ST, Demyttenaere, K. Difficult-to-treat depression: a clinical and research roadmap for when remission is elusive. Aust N Z J Psychiatry. 2019;53:109–118.
Fava, M, Papakostas, GI, Petersen, T, Mahal, Y, Quitkin, F, Stewart, J, et al.Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry. 2003;15:17–22.
Souery, D, Amsterdam, J, de Montigny, C, Lecrubier, Y, Montgomery, S, Lipp, O, et al.Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9:83–91.
Berlim, MT, , Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry. 2007;52:46–54.
Ruhé, HG, Van Rooijen, G, Spijker, J, Peeters, FPML, Schene, AH. Staging methods for treatment resistant depression. A systematic review. J Affect Disord. 2012;137:35–45.
Fekadu, A, Wooderson, S, Donaldson, C, Markopoulou, K, Masterson, B, Poon, L, et al.A multidimensional tool to quantify treatment resistance in depression: the Maudsley Staging Method. J Clin Psychiatry. 2009;70:177–184.
Caraci, F, Calabrese, F, Molteni, R, Bartova, L, Dold, M, Leggio, GM, et al.International Union of Basic and Clinical Pharmacology CIV: the neurobiology of treatment-resistant depression: from antidepressant classifications to novel pharmacological targets. Pharmacol Rev. 2018;70:475–504.
Schwert, C, Stohrer, M, Aschenbrenner, S, Weisbrod, M, Schröder, A. Biased neurocognitive self-perception in depressive and in healthy persons. J Affect Disord. 2018;232:96–102.
Miskowiak, KW, Petersen, JZ, Ott, CV, Knorr, U, Kessing, LV, Gallagher, P, et al.Predictors of the discrepancy between objective and subjective cognition in bipolar disorder: a novel methodology. Acta Psychiatr Scand. 2016;134:511–521.
Srisurapanont, M, Suttajit, S, Eurviriyanukul, K, Varnado, P. Discrepancy between objective and subjective cognition in adults with major depressive disorder. Sci Rep. 2017;7:1–7.
Petersen, JZ, Porter, RJ, Miskowiak, KW. Clinical characteristics associated with the discrepancy between subjective and objective cognitive impairment in depression. J Affect Disord. 2019;246:763–774.
Serra-Blasco, M, Torres, IJ, Vicent-Gil, M, Goldberg, X, Navarra-Ventura, G, Aguilar, E, et al.Discrepancy between objective and subjective cognition in major depressive disorder. Eur Neuropsychopharmacol. 2019;29:46–56.
Gupta, M, Holshausen, K, Best, MW, Jokic, R, Milev, R, Bernard, T, et al.Relationships among neurocognition, symptoms, and functioning in treatment-resistant depression. Arch Clin Neuropsychol. 2013;28:272–281.
Snyder, HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull. 2014;139:81–132.
McClintock, SM, Husain, MM, Greer, TL, Cullum, CM. Association between depression severity and neurocognitive function in major depressive disorder: a review and synthesis. Neuropsychology. 2010;24:9–34.
Bortolato, B, Miskowiak, KW, Köhler, CA, Maes, M, Fernandes, BS, Berk, M, et al.Cognitive remission: a novel objective for the treatment of major depression? BMC Med. 2016;14:9.
Evans, VC, Iverson, GL, Yatham, LN, Lam, RW. The relationship between neurocognitive and psychosocial functioning in major depressive disorder: a systematic review. J Clin Psychiatry. 2014;75:1359–1370.
Goodall, J, Fisher, C, Hetrick, S, Phillips, L, Parrish, EM, Allott, K. Neurocognitive functioning in depressed young people: a systematic review and meta-analysis. Neuropsychol Rev. 2018;28:216–231.
Keefe, RSE, McClintock, SM, Roth, RM, Murali Doraiswamy, P, Tiger, S, Madhoo, M. Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. J Clin Psychiatry. 2014;75:864–876.
Allott, K, Fisher, CA, Amminger, GP, Goodall, J, Hetrick, S. Characterizing neurocognitive impairment in young people with major depression: state, trait, or scar? Brain Behav. 2016;6:1–12.
Stordal, KI, Lundervold, AJ, Egeland, J, Mykletun, A, Asbjørnsen, A, Landrø, NI, et al.Impairment across executive functions in recurrent major depression. Nord J Psychiatry. 2004;58:41–47.
Paradiso, S, Lamberty, GJ, Garvey, MJ, Robinson, RG. Cognitive impairment in the euthymic phase of chronic unipolar depression. J Nerv Ment Dis. 1997;185:748–754.
Jaeger, J, Berns, S, Uzelac, S, Davis-Conway, S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145:39–48.
Bruder, GE, Alvarenga, JE, Alschuler, D, Abraham, K, Keilp, JG, Hellerstein, DJ, et al.Neurocognitive predictors of antidepressant clinical response. J Affect Disord. 2014;166:108–114.
Gallagher, P, Robinson, LJ, Gray, JM, Young, AH, Porter, RJ. Neurocognitive function following remission in major depressive disorder: potential objective marker of response? Aust N Z J Psychiatry. 2007;41:54–61.
Story, TJ, Potter, GG, Attix, DK, Welsh-Bohmer, KA, Steffens, DC. Neurocognitive correlates of response to treatment in late-life depression. Am J Geriatr Psychiatry. 2008;16:752–759.
Potter, GG, Kittinger, JD, Wagner, HR, Steffens, DC, Krishnan, KRR. Prefrontal neuropsychological predictors of treatment remission in late-life depression. Neuropsychopharmacology. 2004;29:2266–2271.
Fournier, JC, DeRubeis, RJ, Shelton, RC, Hollon, SD, Amsterdam, JD, Gallop, R. Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. J Consult Clin Psychol. 2009;77:775–787.
Dunkin, JJ, Leuchter, AF, Cook, IA, Kasl-Godley, JE, Abrams, M, Rosenberg-Thompson, S. Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord. 2000;60:13–23.
Gorlyn, M, Keilp, JG, Grunebaum, MF, Taylor, BP, Oquendo, MA, Bruder, GE, et al.Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm. 2008;115:1213–1219.
Malhi, GS, Byrow, Y. Is treatment-resistant depression a useful concept? Evid Based Ment Health. 2016;19:1–3.
Lezak, MD, Howieson, DB, Loring, DW, with Hannay, HJ, Fischer, JS. Neuropsychological assessment. 4th ed.Oxford, UK: Oxford University Press, 2004.
Sackeim, HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):10–17.
Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
Lam, RW, Saragoussi, D, Danchenko, N, Rive, B, Lamy, FX, Brevig, T. Psychometric validation of Perceived Deficits Questionnaire–Depression (PDQ-D) in patients with major depressive disorder (MDD). Value Heal. 2013;16:A330.
Strober, LB, Binder, A, Nikelshpur, OM, Chiaravalloti, N, DeLuca, J. The perceived deficits questionnaire: perception, deficit, or distress? Int J MS Care. 2016;18:183–190.
Sullivan, M, Edgley, K, Dehoux, E. A survey of multiple sclerosis: I. Perceived cognitive problems and compensatory strategy use. Can J Rehabil. 1990;4:99–105.
Dickson, AL. Book review: Lezak, Muriel Deutsch, (1983). Neuropsychological assessment (2nd ed.). New York: Oxford University Press. J Psychoeduc Assess. 1986;4:91–92.
Strauss, E, Sherman, E, Spreen, O. A compendium of neuropsychological tests: administration, norms, and commentary. 3rd ed. New York, NY: Oxford University Press, 2006.
Casals-Coll, M, Sánchez-Benavides, G, Quintana, M, Manero, RM, Rognoni, T, Calvo, L, et al.Estudios normativos españoles en población adulta joven (proyecto NEURONORMA jóvenes): normas para los test de fluencia verbal. Neurología. 2013;28:33–40.
Peña-Casanova, J, Quiñones-Úbeda, S, Gramunt-Fombuena, N, Quintana-Aparicio, M, Aguilar, M, Badenes, D, et al.Spanish multicenter normative studies (NEURONORMA project): norms for verbal fluency tests. Arch Clin Neuropsychol. 2009;24:395–411.
Nemeroff, CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68(suppl 8):17–25.
Schosser, A, Serretti, A, Souery, D, Mendlewicz, J, Zohar, J, Montgomery, S, et al.European Group for the Study of Resistant Depression (GSRD)—where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol. 2012;22:453–468.
Kautzky, A, Baldinger-Melich, P, Kranz, GS, Vanicek, T, Souery, D, Montgomery, S, et al.A new prediction model for evaluating treatment-resistant depression. J Clin Psychiatry. 2017;78:215–222.
Zheng, W, Zhou, Y-L, Liu, W-J, Wang, C-Y, Zhan, Y-N, Li, H-Q, et al.Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder. J Affect Disord. 2019;246:241–247.
Raes, F, Sienaert, P, Demyttenaere, K, Peuskens, J, Williams, JMG, Hermans, D. Overgeneral memory predicts stability of short-term outcome of electroconvulsive therapy for depression. J ECT. 2008;24:81–83.
Kavanaugh, BC, Aaronson, ST, Clarke, GN, Holtzheimer, PE, Johnson, CW, McDonald, WM, et al.Neurocognitive effects of repetitive transcranial magnetic stimulation with a 2-coil device in treatment-resistant major depressive disorder. J ECT. 2018;34:258–265.
Romeo, B, Choucha, W, Fossati, P, Rotge, J-Y. Clinical and biological predictors of ketamine response in treatment-resistant major depression: review. Encephale. 2017;43:354–362.
Campbell, S, MacQueen, G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci. 2004, 2004;29:417–426.
Shah, PJ, Ebmeier, KP, Glabus, MF, Goodwin, GM. Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry. 1998;172:527–532.
Seeberg, I, Kjaerstad, HL, Miskowiak, KW. Neural and behavioral predictors of treatment efficacy on mood symptoms and cognition in mood disorders: a systematic review. Front Psychiatry. 2018;9:337.
Dickerson, BC, Eichenbaum, H. The episodic memory system: neurocircuitry and disorders. Neuropsychopharmacology. 2010;35:86–104.
Rolls, ET. The storage and recall of memories in the hippocampo-cortical system. Cell Tissue Res. 2018;373:577–604.
MacQueen, G, Frodl, T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research? Mol Psychiatry. 2011;16:252–264.
Joober, R, Rouleau, GA, Lal, S, Dixon, M, O’Driscoll, G, Palmour, R, et al.Neuropsychological impairments in neuroleptic-responder vs. non-responder schizophrenic patients and healthy volunteers. Schizophr Res. 2002;53:229–238.
de Bartolomeis A, , Balletta, R, Giordano, S, Buonaguro, EF, Latte, G, Iasevoli, F. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Res. 2013;210:387–395.
Wild, J, Gur, RC. Verbal memory and treatment response in post-traumatic stress disorder. Br J Psychiatry. 2008;193:254–255.
Chao, LL. Evidence of objective memory impairments in deployed Gulf War veterans with subjective memory complaints. Mil Med. 2017;182:e1625–e1631.
Scott, JC, Matt, GE, Wrocklage, KM, Crnich, C, Jordan, J, Southwick, SM, et al.A quantitative meta-analysis of neurocognitive functioning in posttraumatic stress disorder. Psychol Bull. 2015;141:105–140.
Hammar, Å, Årdal, G. Verbal memory functioning in recurrent depression during partial remission and remission-brief report. Front Psychol. 2013;4:652.
Peters, AT, Jacobs, RH, Crane, NA, Ryan, KA, Weisenbach, SL, Ajilore, O, et al.Domain-specific impairment in cognitive control among remitted youth with a history of major depression. Early Interv Psychiatry. 2017;11:383–392.
Huang, CL-C. Residual cognitive deficit in adults with depression who recovered after 6-month treatment: stable versus state-dependent markers. J Clin Med Res. 2009;1:202–206.
Miskowiak, KW, Vinberg, M, Macoveanu, J, Ehrenreich, H, Køster, N, Inkster, B, et al.Effects of erythropoietin on hippocampal volume and memory in mood disorders. Biol Psychiatry. 2015;78:270–277.